

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
06 December 2018 (06.12.2018)



(10) International Publication Number
WO 2018/222722 A2

(51) International Patent Classification:
A61K 39/395 (2006.01)

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:
PCT/US2018/035142

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

(22) International Filing Date:
30 May 2018 (30.05.2018)

Published:

— without international search report and to be republished
upon receipt of that report (Rule 48.2(g))
— with sequence listing part of description (Rule 5.2(a))

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/512,644 30 May 2017 (30.05.2017) US
62/513,816 01 June 2017 (01.06.2017) US

(71) Applicant: **BRISTOL-MYERS SQUIBB COMPANY**
[US/US]; Rt. 206 & Province Line Road, Princeton, New
Jersey 08543 (US).

(72) Inventors: **BURTON, Lori S.**; 59 Eldrige Drive, Rob-
binsville, New Jersey 08691 (US). **YING, William**; 1082
Mayflower Ct., Martinsville, New Jersey 08836 (US).
LONBERG, Nils; c/o Bristol-Myers Squibb Company,
700 Bay Road, Redwood City, California 94063 (US).
CHAKRAVARTHI, Sudhir; 23 Chatsworth Road, Man-
alapan, New Jersey 07726-4186 (US). **SMITH, Pedro**;
7636 Crane Crossing, Crane Crossing, Pennsylvania 18062
(US).

(74) Agent: **CALVO, Paul A.** et al.; Sterne, Kessler, Goldstein
& Fox P.L.L.C., 1100 New York Avenue, NW, Washing-
ton, District of Columbia 20005 (US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TJ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

(54) Title: COMPOSITIONS COMPRISING AN ANTI-LAG-3 ANTIBODY OR AN ANTI-LAG-3 ANTIBODY AND AN AN-
TI-PD-1 OR ANTI-PD-L1 ANTIBODY

(57) Abstract: This provides pharmaceutical compositions that comprise (i) an anti-LAG-3 antibody or antigen binding fragment thereof or (ii) an anti-LAG-3 antibody or antigen binding fragment thereof and an anti-PD-1 antibody, anti-PD-L1 antibody, or antigen binding fragment thereof. Also provided are pharmaceutical compositions that comprise a buffering agent, stabilizing or bulking agent, and a surfactant. The disclosure also provides a vial, syringe, intravenous bag, or kit that comprises the compositions, and methods for using the compositions.



WO 2018/222722 A2